IntelGenx Provides Update on Phase 2a Montelukast VersaFilm Clinical Trial
IntelGenx (TSXV:IGX,OTCQX:IGXT) a leading oral drug delivery company, provided an update on its Phase 2a study of Montelukast VersaFilm in patients with mild to moderate Alzheimer’s Disease (AD). As quoted in the press release: To date, seven study sites across Canada have randomized eight subjects, many of which commenced dosing in late-2018. IntelGenx sponsored study … Continued
IntelGenx (TSXV:IGX,OTCQX:IGXT) a leading oral drug delivery company, provided an update on its Phase 2a study of Montelukast VersaFilm in patients with mild to moderate Alzheimer’s Disease (AD).
As quoted in the press release:
To date, seven study sites across Canada have randomized eight subjects, many of which commenced dosing in late-2018. IntelGenx sponsored study sites are actively screening for new patients and IntelGenx expects enrollment to accelerate following the holiday season hiatus. In addition to opening its planned eighth trial site, IntelGenx is preparing to open an additional site in Montreal, bringing the total number of sites to nine.
“We are looking forward to commencing patient recruitment at our eighth site in the coming weeks, as well as opening an additional site in Montreal by the end of first quarter 2019,” said Dr. Horst G. Zerbe, President and CEO of IntelGenx. “Although in its early stages, this is an exciting trial for IntelGenx as we work with our study sites to achieve a shared goal of finding a treatment that benefits patients living with this most unfortunate and debilitating disease.”
“Unlike traditional dosage forms, our Montelukast VersaFilm™ is engineered to deliver Montelukast with an improved bioavailability, which may be more efficacious than known Montelukast dosage forms in crossing the blood-brain barrier,” contends Dr. Zerbe. “As a result, our VersaFilm™ technology has the potential to be broadly applicable to a wide variety of other pharmaceutical treatment options.”
